"We have completed two-phase trials so far, in which about 100 people were included. The results of which have been quite substantial," Dr. Shirish Arya of Tata Hospital said.
A new study found that obese people are more likely to develop monoclonal gammopathy of undetermined significance (MGUS), a benign blood condition that usually arises before multiple myeloma.
In a story of selflessness that transcends the battlefield, two remarkable Army personnel Captain Cyrus and Fezal have become heroes not with weapons but with a life-saving stem cell donation.
According to a recent study, there is a higher likelihood of monoclonal gammopathy of unknown significance (MGUS), a benign blood disorder that frequently occurs before multiple myeloma, among obese individuals.
The youth was studying in Gujarat's Rashtriya Raksha Shakti University and sought help due to his financial inability to return to his home in Telangana.
New Delhi [India], December 19: Atul Kapur, a 47-year-old ambitious IT professional and doting father of a two-and-a-half-year-old, is facing a life-threatening battle with blood cancer. His dreams took an unexpected turn when he was diagnosed with Acute Myeloid Leukaemia (AML). Now, his onl
Navi Mumbai (Maharashtra) [India], November 1: In a heartfelt struggle against overwhelming odds, 18-year-old Vedant, hailing from Navi Mumbai, is bravely facing blood cancer. His father, Ramdas Laxman, has taken on a challenging mission to raise funds through Impact Guru, aiming to secure t
Patients with multiple myeloma who received idecabtagene vicleucel, popularly known as "ide-cel," a chimeric antigen receptor (CAR) T-cell treatment, had no difference in overall survival outcomes regardless of race or ethnicity.
According to a study published in Blood Advances, patients with multiple myeloma who received idecabtagene vicleucel, also known as "ide-cel," a chimeric antigen receptor (CAR) T-cell treatment, exhibited no change in overall survival outcomes regardless of race or ethnicity.
A group led by scientists at The University of Texas at Austin has discovered a brand-new, bio-inspired medication that restores the capability of immune cells to combat cancer. The medication increases the effectiveness of immunotherapy and inhibits tumour growth in mice models of melanoma,
People with multiple myeloma, a blood malignancy of plasma cells in the bone marrow, have a poorer overall survival rate when compared to individuals without diabetes. This difference in survival due to diabetes was found in white patients in a subgroup analysis but not in black patients, ac